House Backs FDA/PDUFA Bills

23 September 1997

The US House of Representatives subcommittee on health has unanimouslyapproved three bills to reform the Food and Drug Administration and also renew the Prescription Drug User Fee Act (Marketletters passim).

The bills, which cover drugs and biologics, food and devices, are expected to be merged into one bill, similar to the legislation already being debated in the Senate.

Representative Sherrod Brown said the difficult process seems to be near its end, and he was not entirely happy with the rush to consider the three bills.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight